ID   CHLA-134
AC   CVCL_6589
DR   IARC_TP53; 23828
DR   Wikidata; Q54812159
RX   PubMed=9850071;
RX   PubMed=11507071;
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=11507071).
ST   Source(s): COG
ST   Amelogenin: X
ST   CSF1PO: 11,13
ST   D13S317: 11
ST   D16S539: 9,12
ST   D18S51: 13,14
ST   D19S433: 12.2,14
ST   D21S11: 31.2,33.2
ST   D2S1338: 17,24
ST   D3S1358: 15
ST   D5S818: 11,13
ST   D7S820: 12,13
ST   D8S1179: 13,14
ST   FGA: 20,23
ST   TH01: 7
ST   TPOX: 8
ST   vWA: 14,16
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Children
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 15
//
RX   PubMed=9850071;
RA   Keshelava N., Seeger R.C., Groshen S., Reynolds C.P.;
RT   "Drug resistance patterns of human neuroblastoma cell lines derived
RT   from patients at different phases of therapy.";
RL   Cancer Res. 58:5396-5405(1998).
//
RX   PubMed=11507071;
RA   Keshelava N., Zuo J.J., Chen P., Waidyaratne S.N., Luna M.C.,
RA   Gomer C.J., Triche T.J., Reynolds C.P.;
RT   "Loss of p53 function confers high-level multidrug resistance in
RT   neuroblastoma cell lines.";
RL   Cancer Res. 61:6185-6193(2001).
//